Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer

Cancer

Volumn 116, Issue 17, 2010, Pages 4197-4205

  Revel Vilk, S ^a   Yacobovich, J ^b   Tamary, H ^b   Goldstein, G ^b   Nemet, S ^b   Weintraub, M ^a   Paltiel, O ^a   Kenet, G ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Central venous catheter; Deep vein thrombosis; Occlusion; Pediatric; Risk factors; Thrombotic complications

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CATHETER OCCLUSION; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CHILD; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; DEMOGRAPHY; EWING SARCOMA; FAMILY HISTORY; GERM CELL TUMOR; HAZARD RATIO; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHODGKIN LYMPHOMA; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; THROMBOPHILIA; CENTRAL VENOUS CATHETERIZATION; COMPLICATION; NEOPLASMS; THROMBOSIS;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; NEOPLASMS; RISK FACTORS; THROMBOSIS;

ANTINEOPLASTIC AGENT;

EID: 77956835201     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25199     Document Type: Article

References (42)

1. Cameron GS. Central venous catheters for children with malignant disease: Surgical issues. J Pediatr Surg. 1987;22:702-704.
2. Iannacci L, Piomelli S. Supportive care for children with cancer. Guidelines of the children's cancer study group. Use of venous access lines. Am J Pediatr Hematol Oncol. 1984;6:277-281.
3. Fratino G, Molinari AC, Parodi S, et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol. 2005;16:648-654. (Pubitemid 40613333)
4. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol. 2006;24:4575-4580.
5. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BMF protocols): prednisone versus dexamethasone administration. Blood. 2003;101:2529-2533. (Pubitemid 36857608)
6. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase: results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer. 2003;97:508-516.
7. Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood. 2003;101:4273-4278.
8. Vossen CY, Rosendaal FR; EPCOT Study Group. Risk of arterial thrombosis in carriers of familial thrombophilia. J Thromb Haemost. 2006;4:916-918.
9. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-332.
10. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74:139-148.
11. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
13. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19:511-518.
14. Abramson JH. WINPEPI (PEPI-for-Windows): Computer programs for epidemiologists. Epidemiol Perspect Innov. 2004;1:6.
15. King MM, Rasnake MS, Rodriguez RG, Riley NJ, Stamm JA. Peripherally inserted central venous catheter-associated thrombosis: retrospective analysis of clinical risk factors in adult patients. South Med J. 2006;99:1073-1077.
16. Ong B, Gibbs H, Catchpole I, Hetherington R, Harper J. Peripherally inserted central catheters and upper extremity deep vein thrombosis. Australas Radiol. 2006;50:451-454.
17. Turcotte S, Dube S, Beauchamp G. Peripherally inserted central venous catheters are not superior to central venous catheters in the acute care of surgical patients on the ward. World J Surg. 2006;30:1605-1619.
18. Male C, Julian JA, Massicotte P, Gent M, Mitchell L. Significant association with location of central venous line placement and risk of venous thrombosis in children. Thromb Haemost. 2005;94:516-521.
19. Farinasso L, Bertorello N, Garbarini L, et al. Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study. Leukemia. 2007;21:552-556.
20. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):887S-986S.
21. Kuhle S, Spavor M, Massicotte P, et al. Prevalence of postthrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost. 2008;6:589-594.
22. Cil BE. Radiological placement of chest ports in pediatric oncology patients. Eur Radiol. 2004;14:2015-2019.
23. Marcy PY, Magne N, Castadot P, et al. Is radiologic placement of an arm port mandatory in oncology patients?: analysis of a large bi-institutional experience. Cancer. 2007;110:2331-2338.
24. Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin. 2008;58:323-346.
25. Basford TJ, Poenaru D, Silva M. Comparison of delayed complications of central venous catheters placed surgically or radiologically in pediatric oncology patients. J Pediatr Surg. 2003;38:788-792.
26. Puel V, Caudry M, Le Metayer P, et al. Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer. 1993;72:2248-2252.
27. Cadman A, Lawrance JA, Fitzsimmons L, Spencer-Shaw A, Swindell R. To clot or not to clot? That is the question in central venous catheters. Clin Radiol. 2004;59:349-355.
28. Caers J, Fontaine C, Vinh-Hung V, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Support Care Cancer. 2005;13:325-331.
29. Bezemer ID, van der Meer FJ, Eikenboom JCJ, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169:610-615.
30. Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008;118:1373-1382.
31. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost. 2003;1:915-921.
32. Flege S, Mitchell L, Kenet G, Heller C, Fruhwald M, Nowak-Gottl U. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study [abstract]. ASH Annual Meeting Abstracts. 2008;112:524.
33. van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol. 2005;23:2655-2660.
34. Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer. 2008;51:792-797.
35. Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol. 2000;18:1269-1278.
36. Aquino VM, Sandler ES, Mustafa MM, Steele JW, Buchanan GR. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters. J Pediatr Hematol Oncol. 2002;24:710-713.
37. Kalmanti M, Germanakis J, Stiakaki E, et al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatr Hematol Oncol. 2002;19:173-179.
38. Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: a children's oncology group study. J Clin Oncol. 2004;22:2718-2723.
39. van Rooden CJ, Schippers EF, Guiot HF, et al. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol. 2008;26:428-433.
40. Cesaro S, Tridello G, Cavaliere M, et al. Prospective, randomized trial of 2 different modalities of flushing central venous catheters in pediatric patients with cancer. J Clin Oncol. 2009;27:2059-2085.
41. Journeycake JM, Eshelman D, Buchanan GR. Post-thrombotic syndrome is uncommon in childhood cancer survivors. J Pediatr. 2006;148:275-277.
42. Ruud E, Holmstrom H, Hopp E, Wesenberg F. Central line-associated venous late effects in children without prior history of thrombosis. Acta Paediatr. 2006;95:1060-1065.